×
{{login.error}}
{{login.verifyresult}}
×
6~16个字符、区分大小写、必须包含字母和数字
6~16个字符、区分大小写、必须包含字母和数字
密码已经重置成功,快去使用新密码吧!
登录账号
密码已经重置成功,快去使用新密码吧! 登录账号
×

注册成功

确认

抗体

单克隆抗体是由单个B 淋巴细胞克隆所分泌的抗体,由于B 淋巴细胞只能产生一种专有的、针对一种抗原决定簇的抗体,所以具有理化性质高度专一、生物活性单一、与抗原结合特异性强等特点。因此,它也被形象地被称为“生物导弹”, 现有的抗体药物大多属于此类抗体。近年来,单克隆抗体药物迅速发展,并逐渐成为生物医药领域发展的主要方向。

TargetMol可为您提供30多种抗体抑制剂,满足您的实验需求。TargetMol始终致力于服务“科研人员”,将热门的研究报道和产品推送给各位科研人员。

产品编号 产品名称
T9962 Mepolizumab Mepolizumab 是一种中和 IL-5 的人源化单克隆抗体。 美泊利单抗可用于严重嗜酸性哮喘和嗜酸性肉芽肿伴多血管炎的研究。
T39730 Datopotamab deruxtecan Datopotamab deruxtecan (DS-1062; Dato-DXd) is a trophoblast cell surface antigen 2 (TROP2)-directed antibody-drug conjugate (ADC) . Datopotamab deruxtecan has a potent antitumor activity.
T39595 Disitamab vedotin Disitamab vedotin (RC48) is an antibody-drug conjugate (ADC) comprising a monoclonal antibody against human epidermal growth factor receptor 2 (HER2) conjugated via a cleavable linker to the cytotoxic agent Monomethyl auristatin E (MMAE). Disitamab vedotin enhances antitumor immunity.
T38951 Isatuximab Isatuximab is a monoclonal antibody targeting the transmembrane receptor and ectoenzyme CD38 , a protein highly expressed on hematological malignant cells, including those in multiple myeloma (MM). Isatuximab has antitumor activity via multiple biological mechanisms, including antibody-dependent cellular-mediated cytotoxicity, complement-dependent cytotoxicity, antibody-dependent cellular phagocytosis, and direct induction of apoptosis without crosslinking. Isatuximab also directly inhibits CD38 ectoenzyme activity, which is implicated in many cellular functions.
T38105 Ixekizumab Ixekizumab (LY2439821) is a humanized IgG4 monoclonal antibody that selectively binds and neutralizes interleukin IL-17A (KD<3 pM). Ixekizumab directly blocks IL-17A binding to IL-17RA (IL-17A receptor) but does not bind to other IL-17 family members. Ixekizumab is used for the research of moderate-to-severe plaque psoriasis[1][2]. The equilibrium KD of Ixekizumab for human and cynomolgus monkey IL-17A were 1.8 pM and 0.8 pM, respectively. Ixekizumab also bound to rabbit IL-17A, but the affinity was lower, and the binding was heterogeneous (KD of 1.3 nM and 14 nM). Ixekizumab shows no binding to either mouse or rat IL-17A[1].Ixekizumab (0.1-10000 pM) inhibits human IL-17A- or human IL-17A/F heterodimer-induced growth-regulated oncogene (GRO)α secretion from HT-29 cells in a dose-dependent fashion. Ixekizumab inhibits cynomolgus monkey IL-17A-induced GROα secretion from HT-29 cells in a dose-dependent fashion[1]. Ixekizumab (0.001-1 mg/kg; i.v.) is able to decrease human IL-17A-induced keratinocyte chemoattractant (KC) secretion in the plasma of the C57BL/6 mice in a dose-dependent manner[1].In male cynomolgus monkeys, following IV administration of 1 mg/kg, Ixekizumab is eliminated with a mean half-life of 6.5 days. After SC administration of 1 mg/kg, Ixekizumab reaches an average maximal plasma concentration of 11.1 μg/mL ~72 hours postdose. The mean elimination half-life following the SC injection was 10.3 days[1]. [1]. Liu L, et al. Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A. J Inflamm Res. 2016;9:39-50. Published 2016 Apr 19.[2]. Griffiths CE, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015;386(9993):541-551.
T36656 Anti-Spike-RBD Single Domain mAb Anti-Spike-RBD Single Domain mAb is a CHO cell derived Alpaca monoclonal VHH-huFc antibody, specifically binds to SARS-CoV-2 RBD with high affinity[1]. [1]. Chunyan Wang, et al. A Human Monoclonal Antibody Blocking SARS-CoV-2 Infection. Nat Commun. 2020 May 4;11(1):2251.
T36655 Anti-Spike-RBD mAb Anti-Spike-RBD mAb is a CHO cell derived human monoclonal IgG1 antibody. Blocking the interaction of spike protein and ACE2 is a potential therapeutic approach for SARS-CoV-2 treatment[1]. [1]. Chunyan Wang, et al. A Human Monoclonal Antibody Blocking SARS-CoV-2 Infection. Nat Commun. 2020 May 4;11(1):2251.
T36654 Anti-SARS-CoV-2 Spike mAb (CR3022) Anti-SARS-CoV-2 Spike mAb (CR3022) is a a CHO cell derived human monoclonal IgG1 antibody. It binds to both S1 domain of SARS-CoV/SARS-CoV-2 Spike protein[1][2]. CR3022 recognizes a cryptic epitope that is only accessible when S protein is in open" conformations[1]. CR3022 binds more tightly to SARS-CoV because its epitope contains a glycan not present in SARS-CoV-2[2].
T36653 Anti-SARS-80R mAb Anti-SARS-80R mAb (SARS-80R) is a human monoclonal IgG1 antibody produced in CHO cells. Anti-SARS-80R mAb can specifically bind to Spike (S1) protein to prevent SARS virus infection of susceptible cells[1]. Anti-SARS-80R mAb against SARS-CoV spike protein that acts as a viral entry inhibitor in vitro[1]. [1]. Sui J, et al. Evaluation of human monoclonal antibody 80R for immunoprophylaxis of severe acute respiratory syndrome by an animal study, epitope mapping, and analysis of spike variants. J Virol. 2005;79(10):5900-5906.
T36652 Anti-MERS-3A1 mAb Anti-MERS-3A1 mAb (MERS-3A1) is a human monoclonal IgG1 antibody with the high binding affinity produced in CHO cells. Anti-MERS-3A1 mAb bocks the binding of MERS-CoV spike protein to DPP4 receptor[1]. [1]. Ali S Omrani, et al. Middle East Respiratory Syndrome Coronavirus (MERS-CoV): Animal to Human Interaction. Pathog Glob Health. 2015;109(8):354-62.
T36651 Anti-MERS-2E6 mAb Anti-MERS-2E6 mAb (MERS-2E6; MERS Antibody-2E6), a human neutralizing antibody IgG1 (CHO expressed) that can compete for the binding of the virus Spike protein to the receptor (CD26), thereby inhibiting virus invasion into host cells.
T36646 Trastuzumab deruxtecan Trastuzumab deruxtecan (DS-8201a) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, and a topoisomerase I inhibitor. Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer[1][2]. Trastuzumab deruxtecan (1 pM-10 nM; 5 days) inhibits the growth of HER2‐positive KPL‐4 cells, with an IC50 of 109.7 pM[2].Trastuzumab deruxtecan (10 nM; 5 days) shows bystander killing effects in HER2‐negative MDA‐MB‐468 cells[2]. Cell Viability Assay[2] Cell Line: KPL‐4 and MDA‐MB‐468 cells Trastuzumab deruxtecan (3 mg/kg; a single i.v.) shows antitumor activity against not only HER2‐positive tumors but also HER2‐negative tumors under the co‐inoculated condition[2].Trastuzumab deruxtecan (10 mg/kg; i.v. on days 0 and 7) inhibits the tumor growth in in EMT6-hHER2 syngeneic mouse model[3]. Animal Model: Female BALB/c nude mice injected with NCI‐N87 and MDA‐MB‐468‐Luc cells[2] [1]. Kotani D, et, al. Trastuzumab deruxtecan for the treatment of patients with HER2-positive gastric cancer. Ther Adv Med Oncol. 2021 Jan 7;13:1758835920986518. [2]. Ogitani Y, et, al. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci. 2016 Jul;107(7):1039-46. [3]. Iwata TN, et, al. [Fam-] trastuzumab deruxtecan (DS-8201a)-induced antitumor immunity is facilitated by the anti-CTLA-4 antibody in a mouse model. PLoS One. 2019 Oct 1;14(10):e0222280.
T35397 Sacituzumab (anti-Trop-2) Sacituzumab (anti-Trop-2) 是一种完全人源化的 IgG1 kappa 单克隆抗体,可以结合Trop-2。
T35395 Camrelizumab (anti-PD-1) Camrelizumab (anti-PD-1)是一种针对PD-1的人源IgG4抗体,抑制PD-L1和PD-L2与PD-1的结合,具有抑制免疫检查点效果和抗肿瘤活性;MW: 146.3 KD。
T35394 Sintilimab (anti-PD-1) Sintilimab (anti-PD-1, IBI 308) 是一种全人源 IgG4 单克隆抗体,可与 T 细胞表面的PD-1结合,阻断 PD-1/PD-配体 1 (PD-L1) 通路,并重新激活 T 细胞以杀死癌细胞。
T35392 Tiragolumab (anti-TIGIT) Tiragolumab (anti-TIGIT) (RG6058, MTIG7192A) 是一种人源化 IgG1/kappa 单克隆抗体,可与TIGIT结合以防止其与其配体 PVR (CD155) 相互作用。
T35391 Vibostolimab (anti-TIGIT) Vibostolimab (anti-TIGIT, MK-7684) 是一种人源化单克隆抗体,与具有免疫球蛋白和 ITIM 结构域 (TIGIT)的 T 细胞免疫受体结合,阻断 TIGIT 与其配体 CD112 和 CD155 之间的相互作用,从而激活 T 淋巴细胞,帮助破坏肿瘤细胞。
T35389 Sarilumab (anti-IL-6Rα) Sarilumab (anti-IL-6Rα)是人源anti-IL-6Rα单克隆抗体,与膜结合的和可溶性的IL-6Rα以高亲和力结合。MW: 144.13 KD。
T35386 Elotuzumab (anti-SLAMF7) Elotuzumab(anti-SLAMF7、BMS-901608、PDL063、HuLuc63)是一种人源化单克隆抗体,可结合人类信号淋巴细胞激活分子 F7(hSLAMF7,也称为 CS1、CD319 或 CRACC)。Elotuzumab 具有双重作用机制,包括直接激活自然杀伤 (NK) 细胞和诱导 NK 细胞介导的抗体依赖性细胞毒性。
T35385 Isatuximab (anti-CD38) Isatuximab (anti-CD38) (SAR650984, hu38SB19) 是一种源自 IgG1 的单克隆抗体,可与CD38 受体的特定细胞外表位结合,kd 为 0.12 nM。
联系我们
400-820-0310
service@tsbiochem.com

上海市静安区江场三路238号8楼